Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Annals of the Rheumatic Diseases|March 19, 2010
Evidence for treating rheumatoid arthritis to target: results of a systematic literature searchMonika Schoels, Rachel Knevel, Daniel Aletaha, et al.
Annals of the Rheumatic Diseases|April 24, 2026
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025Kevin L Winthrop, Andreas Kerschbaumer, John D Isaacs, et al.
Annals of Internal Medicine|March 21, 2007
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trialYvonne P M Goekoop-Ruiterman, Jeska K de Vries-Bouwstra, Cornelia F Allaart, et al.
Annals of the Rheumatic Diseases|December 20, 2023
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, et al.
Annals of Neurology|March 14, 2002
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placeboUmesh A Badrising, Marion L C Maat-Schieman, Michel D Ferrari, et al.
Current Medical Research and Opinion|December 15, 2010
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RAJosef S Smolen, Maarten Boers, Eric C Abadie, et al.
Annals of the Rheumatic Diseases|March 11, 2010
Treating rheumatoid arthritis to target: recommendations of an international task forceJosef S Smolen, Daniel Aletaha, Johannes W J Bijlsma, et al.
Annals of the Rheumatic Diseases|August 2, 2011
Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaireBoulos Haraoui, Josef S Smolen, Daniel Aletaha, et al.
Annals of the Rheumatic Diseases|September 26, 2009
Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trialRobert B M Landewé, Jos G A Houbiers, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|May 7, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsJosef S Smolen, Robert Landewé, Ferdinand C Breedveld, et al.
Pageof 9